2021 American Transplant Congress
Late Subclinical Rejection and Borderline Rejection in Kidney Transplant Patients is Associated with Increased Incidence of Subsequent Clinical Rejections
*Purpose: The outcomes of inflammatory changes noted in late surveillance biopsies (1 year) is unclear.*Methods: Patients transplanted (live donor and deceased donor) at our center…2021 American Transplant Congress
Limited Immunogenicity of a Single Dose of Sars-cov-2 Mrna Vaccine in Solid Organ Transplant Recipients
*Purpose: Given substantial challenges with vaccine allocation and evidence for short-term vaccine efficacy after a single dose of SARS-CoV-2 mRNA vaccines in clinical trials, some…2021 American Transplant Congress
Successful Induction of Hematopoietic Chimerism by Dual Inhibition of Mcl-1 and Bcl-2 Without Myeloablative Treatments in Nonhuman Primates
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
*Purpose: Induction of hematopoietic chimerism by donor bone marrow transplantation (BMT) is essential for achievement of allograft tolerance in clinical HLA mismatched kidney transplantation, while…2021 American Transplant Congress
Clinical Outcomes Associated with Induction Therapy Regimens for Kidney Transplantation in Children: A NAPRTCS and PHIS Collaborative Report
*Purpose: Choice of induction agent at the time of pediatric kidney transplant (KTx) is often based upon patient characteristics and center practice. There are limited…2021 American Transplant Congress
Center Use of Technical Variant Grafts Impacts Pediatric Liver Transplant Waitlist and Recipient Outcomes in the United States
*Purpose: Assessing composite outcome measures are critical when evaluating graft type selection in pediatric liver transplantation (LT).*Methods: OPTN data on children listed for first-time LT…2021 American Transplant Congress
Single-Cell RNA-seq Identifies Intra-Graft Population Heterogeneity in Acute Heart Allograft Rejection in the Mouse
*Purpose: Transplant rejection remains a major barrier to graft survival and involves a diversity of cell types. But the heterogeneity in a given cell type…2021 American Transplant Congress
De Novo Hepatitis B Infection Following Liver Transplant with Hepatitis B Core Antibody Positive Graft
*Purpose: The risk of de novo HBV infection in liver transplant recipients of Hepatitis B core antibody (HBcAb) positive donor organs is tempered by availability…2021 American Transplant Congress
Black Patients with Cirrhosis Have Longer Length of Stay and Higher Mortality When Hospitalized
*Purpose: Black patients with cirrhosis have been shown to have higher liver-related mortality compared to White patients. However, little knowledge exists about racial differences related…2021 American Transplant Congress
Understanding Transplant Decision Making Concerns for African, Caribbean and Black Canadian Patients with End-Stage Kidney Disease
*Purpose: Compared to White Canadians, African, Caribbean and Black (ACB) Canadians with end stage kidney disease (ESKD) are less likely to receive a living donor…2021 American Transplant Congress
Belatacept and Carfilzomib-based Treatment of Active Antibody-mediated Rejection in a Sensitized Nonhuman Primate Model
*Purpose: One third of sensitized, HLA-incompatible transplant recipients experience antibody-mediated rejection (AMR) with limited effective treatment options. We tested a novel treatment strategy for AMR…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 139
- Next Page »